Fecha de publicación: -- Fuente: PubMed "Cannabis" Pharmacol Res. 2026 Sep 24:109641. doi: 10.1016/j.phrs.2026.109641. Online ahead of print.ABSTRACTAdenosine regulates neurotransmission, immunity, inflammation, and tissue protection via four G protein-coupled receptors, among which the adenosine A3 receptor (A3R) remains comparatively understudied despite its therapeutic promise. This study examined whether cannabidiol (CBD) and cannabigerol (CBG) modulate human A3R signalling, alone or with added adenosine, using cAMP assays, molecular docking, binding-energy calculations, and molecular dynamics simulations. Both cannabinoids inhibited forskolin-stimulated cAMP accumulation in A3R-expressing cells, an effect absent in non-transfected cells and blocked by the selective A3R antagonist PSB-10 but not by the selective A2A receptor antagonist SCH 58261, supporting A3R-mediated activity under these conditions. CBG was more potent than CBD (IC50 = 0.130 vs. 1.05µM), whereas their maximal inhibitory responses were comparable. In the presence of 100nM CBD, the apparent IC50 of adenosine decreased from 138 to 42nM, whereas 100nM CBG reduced it to 1.0nM, corresponding to an approximately 138-fold increase in apparent adenosine potency; CBG also increased the maximal inhibitory response. These results identify CBG as an effective enhancer of adenosine potency at human A3R, suggesting it stabilizes an occupancy-dependent secondary pose that fine-tunes the orthosteric agonist-receptor interaction network. Further work, encompassing direct binding studies, proximal signalling assays, receptor-subtype profiling, and structural analyses, is needed to validate this mechanism.PMID:42785538 | DOI:10.1016/j.phrs.2026.109641